Apoptosis or necrosis for tumor immunotherapy: What's in a name?

Alan Melcher, Michael Gough, Stephen Todryk, Richard Vile

Research output: Contribution to journalReview articlepeer-review

106 Scopus citations

Abstract

Here we discuss how the mechanisms by which tumor cells are killed in vivo by gene transfer affects their immunogenicity. Our own work has shown that necrotic cell death induces immunological activation signals which recruit, load, activate and mature appropriate subsets of antigen-presenting cells. In contrast, for apoptotic cell death to be immunogenic, signals additional to cell death alone must be provided within the milieu of the dying tumor. Our conclusion is that the immunogenicity of tumor killing is determined by a combination of factors, including the mechanism of killing, the levels of cell death, the local environment that exists within the dying tumor and, as a result, the nature of the immune/scavenger cells which are present at the time of antigen release. Knowledge of how these factors can influence the immune system and lead to the breaking of tolerance to tumor- associated antigens, can potentially be exploited in the design of effective immunotherapies for cancer using gene transfer.

Original languageEnglish (US)
Pages (from-to)824-833
Number of pages10
JournalJournal of Molecular Medicine
Volume77
Issue number12
DOIs
StatePublished - 1999

Keywords

  • Apoptosis
  • Gene therapy
  • Immunotherapy
  • Necrosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'Apoptosis or necrosis for tumor immunotherapy: What's in a name?'. Together they form a unique fingerprint.

Cite this